Isofol Medical Overview

  • Founded
  • 2008
Founded
  • Status
  • Public
  • Employees
  • 12
Employees
  • Stock Symbol
  • ISOFOL
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $1.96
  • (As of Thursday Closing)

Isofol Medical General Information

Description

Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. It's products used for increase efficacy and reduce the side effects of antimetabolite cancer treatment.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Other Healthcare Services
Hospitals/Inpatient Services
Stock Exchange
STO
Primary Office
  • Biotech Center
  • Arvid Wallgrens Backe 20
  • 413 46 Gothenburg
  • Sweden
+46 031-797 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Isofol Medical Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.96 $1.94 $0.40 - $2.16 $162M 83.4M 250K -$0.30

Isofol Medical Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 149,012 50,093 60,165 37,827
Revenue 1,948 0 0 1
EBITDA (19,468) (16,901) (9,462) (8,409)
Net Income (20,308) (17,084) (9,553) (8,428)
Total Assets 20,911 15,666 32,101 44,130
Total Debt 226 295 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Isofol Medical Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Isofol Medical‘s full profile, request access.

Request a free trial

Isofol Medical Executive Team (7)

Name Title Board Seat Contact Info
Gustaf Albert Chief Financial Officer
Roger Tell Chief Medical Officer & Chief Scientific Officer
Sven Erickson Chief Commercial Officer
Bengt Gustavsson Co-Founder
Karin Ganlöv Senior Medical Director
You’re viewing 5 of 7 executive team members. Get the full list »

Isofol Medical Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Isofol Medical Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 01-Jan-2010 00000 0000000 Drug Discovery
To view Isofol Medical’s complete investments history, request access »